Abstract
Different substitutions of imidazolones were synthesized and screened first for the in vitro anticancer activity at concentrations of 12.5 – 100 μg/ ml on Hela cell lines. Out of these eight synthesized compounds, the most active compound 3C-BRS was selected for in vivo anticancer activity using Ehrlich ascites carcinoma (EAC), using liquid tumor model. So 3CBRS was found be an effective anticancer agent.
Original language | English |
---|---|
Pages (from-to) | 933-942 |
Number of pages | 10 |
Journal | Pharmacologyonline |
Volume | 2 |
Publication status | Published - 30-08-2009 |
All Science Journal Classification (ASJC) codes
- Pharmacology
- Drug Discovery